

# Andreas A Argyriou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201453/publications.pdf>

Version: 2024-02-01

99  
papers

3,298  
citations

186265  
28  
h-index

161849  
54  
g-index

99  
all docs

99  
docs citations

99  
times ranked

3702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology, 2012, 82, 51-77.	4.4	441
2	A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews, 2008, 34, 368-377.	7.7	275
3	Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Management and Research, 2014, 6, 135.	1.9	222
4	Peripheral nerve damage associated with administration of taxanes in patients with cancer. Critical Reviews in Oncology/Hematology, 2008, 66, 218-228.	4.4	211
5	Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer, 2013, 119, 438-444.	4.1	179
6	Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation. Journal of Pain and Symptom Management, 2006, 32, 237-244.	1.2	113
7	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics, 2018, 15, 178-189.	4.4	92
8	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer, 2013, 119, 3570-3577.	4.1	86
9	Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica, 2007, 46, 1131-1137.	1.8	80
10	Bortezomib-induced peripheral neurotoxicity: an update. Archives of Toxicology, 2014, 88, 1669-1679.	4.2	73
11	Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. Supportive Care in Cancer, 2006, 14, 223-229.	2.2	71
12	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nature Reviews Neurology, 2017, 13, 492-504.	10.1	68
13	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. Journal of the Peripheral Nervous System, 2014, 19, 299-306.	3.1	67
14	Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?. Supportive Care in Cancer, 2005, 13, 647-651.	2.2	54
15	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-320969.	1.9	43
16	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S74-S85.	3.1	42
17	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 899-902.	2.3	37
18	Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. Journal of the Peripheral Nervous System, 2019, 24, S6-S12.	3.1	37

#	ARTICLE	IF	CITATIONS
19	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the <scp>Clâ€PeriNomS</scp> study. Journal of the Peripheral Nervous System, 2014, 19, 127-135.	3.1	36
20	Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 135-143.	1.6	36
21	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. Journal of the Peripheral Nervous System, 2015, 20, 15-23.	3.1	34
22	Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, S13-S25.	3.1	34
23	The Fire Within: NF-ÎB Involvement in Non-Small Cell Lung Cancer. Cancer Research, 2020, 80, 4025-4036.	0.9	34
24	Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S40-S51.	3.1	33
25	Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S63-S73.	3.1	32
26	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. Clinical Cancer Research, 2020, 26, 5438-5447.	7.0	32
27	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. Journal of the Peripheral Nervous System, 2020, 25, 171-177.	3.1	32
28	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cellular Oncology (Dordrecht), 2011, 34, 381-391.	4.4	31
29	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S52-S62.	3.1	30
30	Paclitaxel plus carboplatin-induced peripheral neuropathy. Journal of Neurology, 2005, 252, 1459-1464.	3.6	28
31	Quality of life and emotional burden of primary caregivers: a case-control study of multiple sclerosis patients in Greece. Quality of Life Research, 2011, 20, 1663-1668.	3.1	28
32	Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. Journal of Headache and Pain, 2018, 19, 87.	6.0	28
33	Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN). Toxics, 2015, 3, 187-197.	3.7	27
34	Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. Journal of Headache and Pain, 2016, 17, 84.	6.0	27
35	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. Supportive Care in Cancer, 2018, 26, 3143-3151.	2.2	23
36	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 5774.	4.1	23

#	ARTICLE	IF	CITATIONS
37	Prospectively assessing serum neurofilament light chain levels as a biomarker of <scp>paclitaxel-induced</scp> peripheral neurotoxicity in breast cancer patients. Journal of the Peripheral Nervous System, 2022, 27, 166-174.	3.1	21
38	Multiple Sclerosis and Reproductive Risks in Women. Reproductive Sciences, 2008, 15, 755-764.	2.5	20
39	Altered expression of NFY-C and RORA in colorectal adenocarcinomas. Acta Histochemica, 2012, 114, 553-561.	1.8	20
40	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 111-119.	3.1	20
41	NSCLC and the alternative pathway of NF- $\kappa$ B: uncovering an unknown relation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 515-523.	2.8	19
42	Psychosocial effects and evaluation of the health-related quality of life in patients suffering from well-controlled epilepsy. Journal of Neurology, 2004, 251, 310-313.	3.6	18
43	An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. Expert Review of Neurotherapeutics, 2021, 21, 475-490.	2.8	18
44	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Critical Reviews in Oncology/Hematology, 2022, 171, 103575.	4.4	18
45	Intracerebral haemorrhage as a rare complication of HSV-1 meningoencephalitis: Case report and review of the literature. Scandinavian Journal of Infectious Diseases, 2006, 38, 63-66.	1.5	17
46	Liability of the Voltage-Gated Sodium Channel Gene <i>SCN2A</i> R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy. Oncology, 2009, 77, 254-256.	1.9	17
47	Assessing the Quality of Sleep in Greek Primary Caregivers of Patients With Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study. Journal of Pain and Symptom Management, 2011, 42, 541-547.	1.2	17
48	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. Supportive Care in Cancer, 2020, 28, 1991-1995.	2.2	17
49	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Review of Neurotherapeutics, 2020, 20, 1005-1016.	2.8	16
50	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. Neurology, 2021, 97, e660-e672.	1.1	16
51	Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. Journal of Biomedical Science, 2015, 22, 98.	7.0	15
52	F-Wave Characteristics as Surrogate Markers of Spasticity in Patients With Secondary Progressive Multiple Sclerosis. Journal of Clinical Neurophysiology, 2010, 27, 120-125.	1.7	14
53	Expression Of Intracellular Components of the NF- $\kappa$ B Alternative Pathway (NF- $\kappa$ B2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients. Scientific Reports, 2019, 9, 14299.	3.3	14
54	Religiosity and its relation to quality of life in primary caregivers of patients with multiple sclerosis: a case study in Greece. Journal of Neurology, 2011, 258, 1114-1119.	3.6	13

#	ARTICLE	IF	CITATIONS
55	Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>International Journal of Neuroscience</i> , 2022, 132, 643-648.	1.6	13
56	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. <i>Neurology</i> , 2020, 95, e1392-e1403.	1.1	13
57	Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 923-944.	2.8	12
58	Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 676-683.	2.1	12
59	Vitamin E for preventing chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2011, 19, 725-726.	2.2	11
60	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	3.1	11
61	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 65-76.	2.8	11
62	The Usefulness of Nerve Conduction Studies in Objectively Assessing Oxaliplatin-Induced Peripheral Neuropathy. <i>Oncologist</i> , 2007, 12, 1371-1372.	3.7	10
63	The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines. <i>Pharmaceutical Biology</i> , 2014, 52, 444-452.	2.9	10
64	Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTÎ²R is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 741.	2.4	10
65	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 1807-1814.	2.2	9
66	NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival. <i>Scientific Reports</i> , 2018, 8, 5259.	3.3	8
67	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 178-183.	3.1	8
68	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. <i>Anti-Cancer Drugs</i> , 2021, 32, 88-94.	1.4	8
69	Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. <i>Journal of Personalized Medicine</i> , 2021, 11, 669.	2.5	8
70	Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 235-248.	2.8	7
71	Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. <i>Journal of Clinical Medicine</i> , 2021, 10, 67.	2.4	7
72	Bilateral drop foot secondary to a primary tumor in the conus medullaris. <i>Muscle and Nerve</i> , 2008, 37, 778-780.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Myasthenia gravis initially presenting with pseudo-internuclear ophthalmoplegia. Neurological Sciences, 2009, 30, 387-388.	1.9	6
74	Destructive Cervical Spine Osteoblastoma at C5 in a Young Patient Initially Presenting with Quadriplegia: Case Report and Review of the Literature. Journal of Emergency Medicine, 2013, 44, e1-e4.	0.7	6
75	A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Expert Review of Neurotherapeutics, 2022, 22, 469-488.	2.8	6
76	Foreign accent syndrome caused by a left temporal-parietal ischaemic stroke. Acta Neuropsychiatrica, 2011, 23, 249-251.	2.1	5
77	Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2021, 26, 43-48.	3.1	5
78	Molecularly Targeted Therapies for Dysimmune Neuropathies. Molecular Medicine, 2009, 15, 283-287.	4.4	4
79	Neurobrucellosis presenting as clinically definite amyotrophic lateral sclerosis. International Journal of Neuroscience, 2018, 128, 686-688.	1.6	4
80	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 360-361.	3.1	4
81	Neuromuscular complications of cancer therapy. Current Opinion in Neurology, 2021, 34, 658-668.	3.6	4
82	Botulinum toxin type a for painful limbs moving extremities. Movement Disorders, 2010, 25, 125-125.	3.9	3
83	Cobalamin deficiency triggering de novo status epilepticus. Epileptic Disorders, 2014, 16, 138-139.	1.3	3
84	The Toxic Neuropathy Consortium of the Peripheral Nerve Society. Journal of the Peripheral Nervous System, 2019, 24, S4-S5.	3.1	3
85	Acute aseptic meningitis during isotretinoin treatment for nodular acne solely presenting with headache: case report and brief review of the literature. International Journal of Neuroscience, 2019, 129, 181-183.	1.6	3
86	Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain. Annals of Translational Medicine, 2018, 6, 127-127.	1.7	3
87	Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. Toxins, 2022, 14, 296.	3.4	3
88	Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine. Toxins, 2022, 14, 434.	3.4	3
89	Irreversible diffuse hypoxic-ischemic encephalopathy, secondary to type I Kounis syndrome. International Journal of Neuroscience, 2020, 130, 746-748.	1.6	2
90	NF- $\kappa$ B2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development. Translational Oncology, 2021, 14, 100912.	3.7	2

#	ARTICLE	IF	CITATIONS
91	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. Annals of Translational Medicine, 2021, 9, 648-648.	1.7	2
92	Cocaine Use and Abuse Triggering Sporadic Young-Onset Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2011, 8, 146-148.	1.4	1
93	Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain. Annals of Translational Medicine, 2018, 6, S78-S78.	1.7	1
94	Natural History of Chemotherapy-Induced Peripheral Neuropathy. , 2021, , 1-18.		1
95	Pneumococcal Otogenic Meningitis Complicated With Pneumocephalus and Coma State. Cureus, 2020, 12, e10917.	0.5	1
96	Hemifacial spasm secondary to hyperhomocysteinaemia-associated cerebral small vessel disease. Acta Neuropsychiatrica, 2011, 23, 89-91.	2.1	0
97	Bee sting-induced acute ischemic stroke: A new manifestation of kounis syndrome?. Annals of Indian Academy of Neurology, 2021, 24, 118-120.	0.5	0
98	Natural Course of Neurotoxicity after Immune Checkpoint Inhibitor (ICI) Exposure. , 2021, , 253-260.		0
99	Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.. Journal of Clinical Oncology, 2012, 30, 9090-9090.	1.6	0